Page last updated: 2024-12-07

l 740093

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 740093: a CCK-B receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132980
CHEMBL ID420783
CHEMBL ID545122
SCHEMBL ID7627122
MeSH IDM0239502

Synonyms (32)

Synonym
CHEMBL420783 ,
l-740093
bdbm50040667
1-[(r)-5-(3-aza-bicyclo[3.2.2]non-3-yl)-1-methyl-2-oxo-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl]-3-m-tolyl-urea; hydrochloride
l-740,093
n-(5-(3-azabicyclo(3.2.2)nonan-3-yl)-2,3-dihydro-1-methyl-2-oxo-1h-1,4-benzodiazepin-3-yl)-n'-(3-methylphenyl)urea
qqm82d8yup ,
l 740,093
urea, n-(5-(3-azabicyclo(3.2.2)non-3-yl)-2,3-dihydro-1-methyl-2-oxo-1h-1,4-benzodiazepin-3-yl)-n'-(3-methylphenyl)-, (r)-
154967-59-6
unii-qqm82d8yup
l 740093
gtpl881
PDSP2_000886
l740093
PDSP1_000900 ,
CHEMBL545122 ,
bdbm50059319
1-[(r)-5-(3-aza-bicyclo[3.2.2]non-3-yl)-1-methyl-2-oxo-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl]-3-m-tolyl-urea
1-[(3r)-5-(3-azabicyclo[3.2.2]nonan-3-yl)-1-methyl-2-oxo-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
SCHEMBL7627122
l-741545
n-[5-(3-azabicyclo[3.2.2]nonan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1h-1,4-benzodiazepin-3-yl]-n'-(3-methylphenyl)carbamimidic acid
DTXSID40935105
Q27078417
(r)-1-(5-(3-azabicyclo[3.2.2]nonan-3-yl)-1-methyl-2-oxo-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)-3-(m-tolyl)urea
188045-76-3
l741545
1-((3r)-5-(3-azabicyclo(3.2.2)nonan-3-yl)-1-methyl-2-oxo-3h-1,4-benzodiazepin-3-yl)-3-(3-methylphenyl)urea
n-((3r)-5-(3-azabicyclo(3.2.2)non-3-yl)-2,3-dihydro-1-methyl-2-oxo-1h-1,4-benzodiazepin-3-yl)-n'-(3-methylphenyl)urea
urea, n-((3r)-5-(3-azabicyclo(3.2.2)non-3-yl)-2,3-dihydro-1-methyl-2-oxo-1h-1,4-benzodiazepin-3-yl)-n'-(3-methylphenyl)-
AKOS040748703

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A bell shaped dose-response curve was noted in the behavioural studies with respect to the interaction between L740,094 and morphine."( L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: electrophysiological and behavioural studies.
Hoffmann, O; Wiesenfeld-Hallin, Z; Xu, XJ, 1996
)
0.29
" In a follow-up study, YM022 and RP73870 were found to produce a rightward shift of the gastrin dose-response curve, which is consistent with competitive inhibition."( Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo.
Ding, XQ; HÃ¥kanson, R, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)1.60000.00000.43624.3000AID50495
Gastrin/cholecystokinin type B receptorHomo sapiens (human)IC50 (µMol)0.00010.00010.36154.0000AID50838
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
gastric acid secretionGastrin/cholecystokinin type B receptorHomo sapiens (human)
cell surface receptor signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationGastrin/cholecystokinin type B receptorHomo sapiens (human)
positive regulation of cell population proliferationGastrin/cholecystokinin type B receptorHomo sapiens (human)
cholecystokinin signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
pH reductionGastrin/cholecystokinin type B receptorHomo sapiens (human)
digestive tract developmentGastrin/cholecystokinin type B receptorHomo sapiens (human)
gland developmentGastrin/cholecystokinin type B receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
cholecystokinin receptor activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
protein bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
gastrin receptor activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
peptide hormone bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
type B gastrin/cholecystokinin receptor bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
1-phosphatidylinositol-3-kinase regulator activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneGastrin/cholecystokinin type B receptorHomo sapiens (human)
intracellular membrane-bounded organelleGastrin/cholecystokinin type B receptorHomo sapiens (human)
plasma membraneGastrin/cholecystokinin type B receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID50838Inhibition of ligand binding to Cholecystokinin type B receptor from guinea pig cortical membrane.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
AID50495Inhibition of ligand binding to Cholecystokinin type A receptor from rat pancreatic tissue.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
AID1346883Human CCK2 receptor (Cholecystokinin receptors)2002Regulatory peptides, Jan-15, Volume: 103, Issue:1
Pharmacological analysis of CCK(2) receptor ligands using COS-7 and SK-N-MC cells, expressing the human CCK(2) receptor.
AID1346809Rat CCK1 receptor (Cholecystokinin receptors)1994Molecular pharmacology, Nov, Volume: 46, Issue:5
Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (75.00)18.2507
2000's4 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.36 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]